London, January 9, 2024 – Abbott today announced it is introducing LingoTM across the UK -- a pioneering biowearable device and app designed to help people improve their overall health and wellbeing. Lingo tracks glucose spikes and dips in real time and provides personalised insights and customised coaching, helping people implement healthier habits and pursue better sleep, mood, focus, energy and fewer unpredictable cravings.
This comes as a welcome announcement with new research commissioned by Abbott revealing that the vast majority (91%) of Brits currently lack energy and nearly one out of every four (22%) people reported that they feel exhausted at the start of the year. 1 While many people have experienced a sugar rush and crash, nearly a third of the nation (30%) are not aware that these glucose spikes and dips impact their metabolism1 and can affect mental and physical wellbeing.2
“Our mood, weight, energy levels and ability to focus are all connected to our individual glucose levels which rise and fall in response to the food we eat, hours of sleep, regular exercise, and even life’s daily stresses,” says Lily Soutter, nutritionist in Abbott’s Lingo business. “Improving your metabolic health by tracking your glucose levels over a meaningful period of time can motivate you to implement changes to better manage those spikes and dips, ultimately benefiting your health and well-being.”
Following more than two decades of research conducted by Abbott’s team of scientists on continuous glucose monitors, and several months of user testing and feedback in the UK to enhance the app, Lingo has been designed to empower people to be in tune with their body’s glucose levels, help create meaningful and healthier habits and, in turn, retrain their metabolism.
“Biowearables are the next evolution of personalised health tech and Lingo is designed to help give people the power to see inside their bodies and take control of their health, and with real-time coaching, make sustainable changes,” says Sarah Tan, Europe general manager of Abbott’s Lingo business. “We’ve combined Abbott’s number one glucose-sensing technology with our personalised coaching app to help guide people to make changes that improve sleep, energy, mood, focus and hunger cravings.”
Lingo coaching starts with a baseline reading of an individual’s glucose through the small Lingo biosensor which is applied to the back of the upper arm and sends data in real time directly to the Lingo app on a smart phone via Bluetooth.
Through algorithms and AI, Lingo learns how an individual’s diet, exercise and sleep can affect their glucose levels and provides recommended actions when their body is experiencing a glucose spike or dip. The coaching then focuses on personalised goals and areas for improvement with recommended challenges that are designed with long-term benefits in mind.
Lingo App Key Features:
Lingo is currently available to purchase in the UK:
The Lingo coaching app is available in the Apple App Store. For more information and to purchase Lingo, please visit HelloLingo.com.
Connect with us at www.hellolingo.com, on Facebook at www.facebook.com/HelloLingo and Instagram @HelloLingo.
The Lingo system is not intended for medical use and is not intended for use in screening, diagnosis, treatment, cure, mitigation, prevention, or monitoring of diseases, including diabetes. The Lingo programme does not guarantee that everyone will achieve the same results as individual responses may vary. It is best to speak to your doctor for advice on starting any diet or exercise regime or if you have an eating disorder or a history of eating disorders. Do not use Lingo if you are pregnant.
About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.
Abbott Media:
Rebecca Rhodes, Public Affairs, Abbott
Rebecca.rhodes@abbott.com
07741101586
References
1 Research conducted by Perspectus Global, November 2023.
2 Jarvis PRE, Cardin JL, Nisevich-Bede PM, McCarter JP. Continuous glucose monitoring in a healthy population: understanding the post-prandial glycemic response in individuals without diabetes mellitus. Metabolism. 2023 Sep;146:155640.
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
FOLLOW ABBOTT